home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

13.64 +0.25 (+1.87%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD ↗

August 15, 2024

This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest...

Via Talk Markets

MNMD Stock Earnings: Mind Medicine Misses EPS for Q2 2024 ↗

August 13, 2024

MNMD stock results show that Mind Medicine missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

August 13, 2024

From Mind Medicine Inc.

Via Business Wire

Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M ↗

August 12, 2024

Via Benzinga

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

August 09, 2024

From Mind Medicine (MindMed) Inc.

Via Business Wire

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

August 09, 2024

From Mind Medicine (MindMed) Inc.

Via Business Wire

MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference

August 06, 2024

From Mind Medicine Inc.

Via Business Wire

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update

August 06, 2024

From Mind Medicine Inc.

Via Business Wire

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗

July 31, 2024

Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.

Via Benzinga

MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

July 29, 2024

From Mind Medicine Inc.

Via Business Wire

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

July 17, 2024

From Mind Medicine Inc.

Via Business Wire

Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗

July 14, 2024

The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...

Via Talk Markets

3 Psychedelic Stocks to Ride to the Moon and Beyond ↗

July 06, 2024

Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market.

Via InvestorPlace

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals ↗

July 04, 2024

Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.

Via InvestorPlace

Clinical-Stage BioTech Drug Stocks Declined 13% In June ↗

July 01, 2024

Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read

Via Talk Markets

MindMed to be Included in Russell 2000® and Russell 3000® Indexes

June 28, 2024

From Mind Medicine Inc.

Via Business Wire

Groundbreaking Fentanyl Vaccine Being Developed To Prevent Fatal Overdoses, Startup Secures $10M ↗

June 26, 2024

The initiative focuses on commercializing academic research aimed at preventing deadly fentanyl from reaching the brain.

Via Benzinga

Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗

June 22, 2024

Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...

Via Talk Markets

MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

June 21, 2024

From Mind Medicine Inc.

Via Business Wire

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

June 20, 2024

From Mind Medicine

Via Business Wire

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024 ↗

June 18, 2024

Discover top strong buy penny stocks, poised for impressive gains as market indices climb, offering unique opportunities.

Via InvestorPlace

Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why ↗

June 09, 2024

Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA.

Via Talk Markets

Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment ↗

June 05, 2024

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.

Via Benzinga

What's Going On With MindMed And Psychedelic Stocks? ↗

June 05, 2024

Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD)....

Via Benzinga

DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

June 05, 2024

Via Benzinga

Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

June 05, 2024

Via Benzinga

Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗

June 05, 2024

Via Benzinga

MindMed to Participate in June Conferences

May 28, 2024

From Mind Medicine Inc.

Via Business Wire

Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week ↗

May 27, 2024

This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our...

Via Talk Markets

The Time Traveler’s Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034 ↗

May 23, 2024

These long-term stocks to buy may seem speculative today, but so did Nvidia in 2024 -- and they may match the chipmaker's returns by 2034.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com